Biowaiver monographs for immediate release solid oral dosage forms: Rifampicin

Journal of Pharmaceutical Sciences

Volumn 98, Issue 7, 2009, Pages 2252-2267

  Becker, C ^a,b   Dressman, J B ^a   Junginger, H E ^c   Kopp, S ^d   Midha, K K ^e   Shah, V P ^f   Stavchansky, S ^g   Barends, D M ^h  

^a GOETHE UNIVERSITY   (Germany)

^b BAYER AG   (Germany)

^c NARESUAN UNIVERSITY   (Thailand)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e UNIVERSITY OF SASKATCHEWAN   (Canada)

^f International Pharmaceutical Federation FIP   (Netherlands)

^g UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^h NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Absorption; Biopharmaceutics classification system (BCS); Dissolution; Permeability; Regulatory science; Rifampicin; Solubility

Indexed keywords

CARBOXYMETHYLCELLULOSE; CASTOR OIL; CELLULOSE; CETYL PALMITATE; CROSCARMELLOSE SODIUM; CROSPOVIDONE; DODECYL SULFATE SODIUM; EXCIPIENT; GELATIN; GLUCOSE; GLYCEROL; HYDROGENATED CASTOR OIL; HYDROXYPROPYLMETHYLCELLULOSE; LACTOSE; MACROGOL; MAGNESIUM STEARATE; NEW DRUG; PALMITIC ACID DERIVATIVE; POLYSORBATE 80; POVIDONE; PROPOLIS; PROPYL PARABEN; PROPYLENE GLYCOL; RIFAMPICIN; RIFAMPICINHEFA N; SILICON DIOXIDE; SIMETHICONE; SORBITOL; STARCH; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

BIOEQUIVALENCE; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG CLASSIFICATION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG MANUFACTURE; DRUG METABOLISM; DRUG OVERDOSE; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG QUALITY; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; EXCIPIENT COMPATIBILITY; FOOD DRUG INTERACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEPROSY; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTITION COEFFICIENT; PKA; REVIEW; SINGLE DRUG DOSE; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT INDICATION; TUBERCULOSIS;

EID: 67650218291     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21624     Document Type: Article

References (140)

1. Vogelpoel H, Welink J, Amidon GL, Junginger HE, Midha KK, Moller H, Olling M, Shah VP, Barends DM. 2004. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci 93:1945-L 1956. (Pubitemid 39045477)
2. WHO. 2006. Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. Technical Report Series, No 937, 40th Report, Annex 8 of WHO Expert committee on specifications for pharmaceutical preparations. http://whqlibdoc.who.int/trs/ WHO-TRS-937-eng.pdf.
3. Kalantzi L, Reppas C, Dressman JB, Amidon GL, Junginger HE, Midha KK, Shah VP, Stavchansky SA, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Acetaminophen (paracetamol). J Pharm Sci 95:4-14.
4. Granero GE, Longhi MR, Becker C, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Acetazolamide. J Pharm Sci 97: 3691-3699.
5. Arnal J, Gonzalez-Alvarez I, Bermejo M, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Aciclovir. J Pharm Sci 97:5061-5073.
6. Manzo RH, Olivera ME, Amidon GL, Shah VP, Dressman JB, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Amitriptyline hydrochloride. J Pharm Sci 95:966-973. (Pubitemid 43731760)
7. Verbeeck RK, Junginger HE, Midha KK, Shah VP, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride. J Pharm Sci 94:1389-1395. (Pubitemid 41168671)
8. Jantratid E, Prakongpan S, Dressman JB, Amidon GL, Junginger HE, Midha KK, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Cimetidine. J Pharm Sci 95:974-984. (Pubitemid 43723158)
9. Chuasuwan B, Binjesoh V, Polli JE, Zhang H, Amidon GL, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Diclofenac sodium and diclofenac potassium. J Pharm Sci, published online: August, 27, 2008.
10. Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Ethambutol dihydrochloride. J Pharm Sci 97:1350-1360.
11. Potthast H, Dressman JB, Junginger HE, Midha KK, Oeser H, Shah VP, Vogelpoel H, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms: Ibuprofen. J Pharm Sci 94:2121-2131. (Pubitemid 41670501)
12. Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Isoniazid. J Pharm Sci 96:522-531. (Pubitemid 46469925)
13. Stosik AG, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Metoclopramide hydrochloride. J Pharm Sci 97:3700-3708.
14. Vogt M, Derendorf H, Kramer J, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Prednisolone. J Pharm Sci 96:27-37. (Pubitemid 46087336)
15. Vogt M, Derendorf H, Kramer J, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Prednisone. J Pharm Sci 96:1480-1489. (Pubitemid 46953764)
16. Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Pyrazinamide. J Pharm Sci 97:3709-3720.
17. Kortejarvi H, Yliperttula M, Dressman JB, Junginger HE, Midha KK, Shah VP, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms: Ranitidine hydrochloride. J Pharm Sci 94:1617-1625. (Pubitemid 41360858)
18. http://www.fip.org/www/index.php?page=ps-sig-bcs.
19. National Libary of Medicine (NLM) and the National Institutes of Health, NCBI, PubMed http://www.pubmed.gov. 2007.
20. National Libary of Medicine (NLM). NCBI Pub- Chem Compound http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?db=pccompound.
21. Medicines Complete. 2007. Pharmaceutical Press, London. http://www.medicinescomplete.com/mc/.
22. World Health Organization (WHO). Library & Information Networks for Knowledge Database (WHOLIS). http://dosei.who.int/uhtbin/cgisirsi/ Mon+Jan+10+13:45:18+MET+2005/0/49.
23. VIDAL BIAM database: Rifampicine (French). http://www.biam2.org.
24. Rote Liste® Service GmbH Frankfurt/Main:ROTE LISTE® Arzneimittelsverzeichnis fü r Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte) (German) (accessed 03-03-2008). http://www.rote-liste.de/Online.
25. VIDAL L'information de référence sur les produits de santé (French). http://www.vidal.fr.
26. World Health Organization (WHO). 1997. Guidance on INN. http://www.who.int/medicines/services/ inn/innquidance/en/.
27. 2008. U.S., Pharmacopeia (USP31-NF26).
28. The Merck Index, 2005. 13th edition.
29. World Health Organization (WHO). 2003. Revision approved June 2004. Treatment of Tuberculosis: Guidelines for national programmes. http://www.emro.who.int/stb/media/ pdf/Guidelines2003. pdf.
30. Treatment of Tuberculosis, American Thoracic Society, CDC, and Infectious Diseases Society of America-United States, 2003. http://www. cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm.
31. World Health Organization (WHO). 2004. Toman's Tuberculosis. Case Detection, Treatment and Monitoring. Second Edition. http://whqlibdoc. who.int/publications/2004/9241546034.pdf, http:// whqlibdoc.who.int/ publications/2004/9241546034- 1.pdf, http://whqlibdoc.who.int/publications/ 2004/ 9241546034-2.pdf, http://whqlibdoc.who.int/publications/ 2004/9241546034-3.pdf , http://whqlibdoc. who.int/publications/2004/9241546034- 4.pdf.
32. WHO Pharmaceuticals Newsletter No.1. 2002. Excerpts from the report of the 24th Annual Meeting of the National Centres participating in the WHOProgramme for International Drug Monitoring. World Health Organization (WHO). http:// www.who.int/medicines/publications/newsletter/ en/news2002-1.pdf.
33. Martindale. 2007. The complete drug reference, electronic version. London: Pharmaceutical Press. http://www.medicinescomplete.com/mc/martindale/ 2006/.
34. AHFS Drug Information. 2007. Electronic version. London: Pharmaceutical Press. http://www.medicinescomplete. com/mc/ahfs/current/.
35. Venkatesan K. 1989. Clinical pharmacokinetic considerations in the treatment of patients with leprosy. Clin Pharmacokinet 16:365-386. (Pubitemid 19167716)
36. Saerens EJ. 1975. The use of rifampicin in the treatment of leprosy. Lepr Rev 46:125-128.
37. Pharm. Eur. Kommentar (German), 20. Lieferung, Vol.6 2005.
38. Update: Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003. &&&http://www. ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list-uids=12904741.
39. Flageul B, Wagner L, Cottenot F. 2001. Immunoallergic accidents with rifamipcin. Acta Leprol 12:71-78.
40. Namisato M, Ogawa H. 2000. Serious side effects of rifampin on the course of WHO/MDT: A case report. Int J Lepr Other Mycobact Dis 68:277-282. (Pubitemid 32151851)
41. Cavenaghi R. 1989. Rifampicin raw material characteristics and their effect on bioavailability. Bull Int Union Tuberc Lung Dis 64:36-37, 40-132 discussion. (Pubitemid 19139212)
42. Henwood SQ, Liebenberg W, Tiedt LR, Lotter AP, de Villiers MM. 2001. Characterization of the solubility and dissolution properties of several new rifampicin polymorphs, solvates, and hydrates. Drug Dev Ind Pharm 27:1017-1030. (Pubitemid 34053197)
43. Pelizza G, Nebuloni M, Ferrari P, Gallo GG. 1977. Polymorphism of rifampicin. Farmaco [Sci] 32:471-481.
44. Agrawal S, Ashokraj Y, Bharatam PV, Pillai O, Panchagnula R. 2004. Solid-state characterization of rifampicin samples and its biopharmaceutic relevance. Eur J Pharm Sci 22:127-144. (Pubitemid 38668679)
45. Henwood SQ, de Villiers MM, Liebenberg W, Lotter AP. 2000. Solubility and dissolution properties of generic rifampicin raw materials. Drug Dev Ind Pharm 26:403-408. (Pubitemid 30207711)
46. World Health Organization (WHO). 2007. The International Pharmacopoeia. General Methods of Analysis, Quality specifications for Pharmaceutical Substances, Excipients and Dosage Forms. 4th Edition 1. Suppl. &&&http://www.who.int/bookorders/anglais/detart1.jsp?sesslan= 1&codlan=1&codcol=15&codcch=4091.
47. European Pharmacopoeia 2008. (6th Edition 2008).
48. Wernigerode SP. Fachinformation Rifampicin- Hefa-N1 (German).
49. SANOFI-AVENTIS RIFADINE® voie oral, rifampicine (French), VIDALPro (L'intégralité de l'information officielle (issue des RCP de l'Afssaps) sur l'ensemble des médicaments commercialisés en France).
50. SANOFI-AVENTIS RIFADINE1 (rifampin capsules USP) and RIFADINE1 IV (rifampin for injection USP); Prescribing information US. http://www.sanofi- aventis.us/live/us/en/ layout.jsp?scat= BD0DB735-32D7-41C4-898F- 74F67D343145.
51. SANDOZ RIMACTANE® 300 mg gélule rifampicine (French), VIDALPro (L'intégralité de l'information officielle (issue des RCP de l'Afssaps) sur l'ensemble des médicaments commercialisés en France).
52. GRÜ NENTHAL Fachinformation Rifa1 Dragees (German).
53. FATOL Fachinformation EREMFAT1 Fatol (German).
54. Singh S, Bhutani H, Mariappan TT, Kaur H, Bajaj M, Pakhale S. 2002. Behavior of uptake of moisture by drugs and excipients under accelerated conditions of temperature and humidity in the absence and the presence of light. 1. Pure antituberculosis drugs and their combinations. Int J Pharm 245:37-44.
55. Prankerd RJ. 2000. Stability of rifampicin in dissolution medium. Int J Pharm 199:111-112.
56. Gallo GG. 1977. Analytical profiles of drug substances and excipients, K. Florey's/H.G. Brittain: Oxford University Press, 5: 467-513.
57. U.S. Department of Health and Human Services Food and Drug Administration Center for Evaluation and Research (CDER). 2000. Guidances for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. http://www.fda.gov/CDER/ GUIDANCE/3618fnl.pdf.
58. European Medicines Evaluation Agency (EMEA). Committee for Proprietary Medicinal Products (CPMP). 2001. Note for Guidance on the Investigation of Bioavailability and Bioequivalence. http://www.emea.eu.int/pdfs/human/ewp/ 140 198en. pdf.
59. World Health Organization (WHO). 2007. Essential Medicines WHO Model List (EML). 15th edition, (revised version March 2007). http://www.who.int/ medicines/publications/08-ENGLISH-indexFINAL-EML15.pdf.
60. Glomme A, Marz J, Dressman JB. 2005. Comparison of a miniaturized shake-flask solubility method with automated potentiometric acid/base titrations and calculated solubilities. J Pharm Sci 94:1-16. (Pubitemid 40116365)
61. Shishoo CJ, Shah SA, Rathod IS, Savale SS, Kotecha JS, Shah PB. 1999. Stability of rifampicin in dissolution medium in presence of isoniazid. Int J Pharm 190:109-123. (Pubitemid 29467478)
62. Becker CDJB. 2006. Biopharmaceutical Characterisation of Rifampicin (Poster). World Meeting on Pharmaceutics Biopharmaceutics and Pharmaceutical Technology, Geneva, March 2006.
63. Clarke's Analysis of Drugs and Poisons, Pharmaceutical Press, London: Electronic version. 2007. Pharmaceutical Press, London, http://www. medicinescomplete.com/mc/clarke/2006/.
64. Seydel JK. 1970. Physico-chemical studies on rifampicin. Antibiot Chemother 16:380-391.
65. Agrawal S, Panchagnula R. 2005. Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms. Biopharm Drug Dispos 26:321-334. (Pubitemid 41684538)
66. Oppolzer W, Prelog V. 1973. The constitution and configuration of rifamycins B, O, S. and SV. Helv Chim Acta 56:2287-2314.
67. Maggi N, Pasqualucci CR, Ballotta R, Sensi P. 1966. Rifampicin: A new orally active rifamycin. Chemotherapy 11:285-292.
68. Maggi N, Pallanza R, Sensi P. 1965. New derivatives of rifamycin SV. Antimicrobial Agents Chemother 5:765-769.
69. Biganzoli E, Cavenaghi LA, Rossi R, Brunati MC, Nolli ML. 1999. Use of a Caco-2 cell culture model for the characterization of intestinal absorption of antibiotics. Farmaco 54:594-599. (Pubitemid 29462620)
70. Artursson P, Borchardt RT. 1997. Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm Res 14:1655-1658. (Pubitemid 28062907)
71. Artursson P, Karlsson J. 1991. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175:880-885.
72. Artursson P, Magnusson C. 1990. Epithelial transport of drugs in cell culture. II: Effect of extracellular calcium concentration on the paracellular transport of drugs of different lipophilicities across monolayers of intestinal epithelial (Caco-2) cells. J Pharm Sci 79:595-600. (Pubitemid 20222724)
73. Artursson P. 1990. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco- 2) cells. J Pharm Sci 79:476-482. (Pubitemid 20221389)
74. Mariappan TT, Singh S. 2003. Regional gastrointestinal permeability of rifampicin and isoniazid (alone and their combination) in the rat. Int J Tuberc Lung Dis 7:797-803. (Pubitemid 36987944)
75. Mariappan TT, Singh S. 2004. Evidence of effluxmediated and saturable absorption of rifampicin in rat intestine using the ligated loop and everted gut sac techniques. Mol Pharm 1:363-367.
76. Acocella G. 1978. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 3:108-127.
77. Holdiness MR. 1984. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 9:511-544.
78. Nitti V, Virgilio R, Patricolo MR, Iuliano A. 1977. Pharmacokinetic study of intravenous rifampicin. Chemotherapy 23:1-6.
79. Loos U, Musch E, Jensen JC, Mikus G, Schwabe HK, Eichelbaum M. 1985. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr 63:1205-1211. (Pubitemid 16169743)
80. Loos U, Musch E, Jensen JC, Schwabe HK, Eichelbaum M. 1987. Influence of the enzyme induction by rifampicin on its presystemic metabolism. Pharmacol Ther 33:201-204. (Pubitemid 17113110)
81. Zhang JN, Liu XG, Zhu M, Chiu FC, Li RC. 1998. Assessment of presystemic factors on the oral bioavailability of rifampicin following multiple dosing. J Chemother 10:354-359. (Pubitemid 28500229)
82. Agrawal S, Singh I, Kaur KJ, Bhade S, Kaul CL, Panchagnula R. 2004. Bioequivalence trials of rifampicin containing formulations: Extrinsic and intrinsic factors in the absorption of rifampicin. Pharmacol Res 50:317-327. (Pubitemid 38844487)
83. Koup JR, Williams-Warren J, Viswanathan CT, Weber A, Smith AL. 1986. Pharmacokinetics of rifampin in children. II. Oral bioavailability. Ther Drug Monit 8:17-22.
84. Koup JR, Williams-Warren J, Weber A, Smith AL. 1986. Pharmacokinetics of rifampin in children. I. Multiple dose intravenous infusion. Ther Drug Monit 8:11-16.
85. Berning SE, Huitt GA, Iseman MD, Peloquin CA. 1992. Malabsorption of antituberculosis medications by a patient with AIDS. N Engl J Med 327:1817-1818.
86. Peloquin CA, Nitta AT, Burman WJ, Brudney KF, Miranda-Massari JR, McGuinness ME, Berning SE, Gerena GT. 1996. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 30:919-925. (Pubitemid 26295240)
87. Choudhri SH, Hawken M, Gathua S, Minyiri GO, Watkins W, Sahai J, Sitar DS, Aoki FY, Long R. 1997. Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea. Clin Infect Dis 25:104-111. (Pubitemid 27293083)
88. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Padmapriyadarsini C, Swaminathan S, Bhagavathy S, Venkatesan P, Sekar L, Mahilmaran A, Ravichandran N, Paramesh P. 2004. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 48:4473-4475. (Pubitemid 39434921)
89. Douglas JG, McLeod MJ. 1999. Pharmacokinetic factors in the modern drug treatment of tuberculosis. Clin Pharmacokinet 37:127-146. (Pubitemid 29431480)
90. Advenier C, Gobert C, Houin G, Bidet D, Richelet S, Tillement JP. 1983. Pharmacokinetic studies of rifampicin in the elderly. Ther Drug Monit 5:61-65.
91. Panchagnula R, Rungta S, Sancheti P, Agrawal S, Kaul CL. 2003. In vitro evaluation of food effect on the bioavailability of rifampicin from antituberculosis fixed dose combination formulations. Farmaco 58:1099-1103.
92. Zent C, Smith P. 1995. Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. Tuber Lung Dis 76:109-113.
93. Peloquin CA, Namdar R, Singleton MD, Nix DE. 1999. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 115:12-18.
94. Buniva G, Pagani V, Carozzi A. 1983. Bioavailability of rifampicin capsules. Int J Clin Pharmacol Ther Toxicol 21:404-409.
95. Polasa K, Krishnaswamy K. 1983. Effect of food on bioavailability of rifampicin. J Clin Pharmacol 23:433-437.
96. Reid J, Marciniuk D, Peloquin CA, Hoeppner V. 2002. Pharmacokinetics of antituberculosis medications delivered via percutaneous gastrojejunostomy tube. Chest 121:281-284. (Pubitemid 34114260)
97. Forgan-Smith R, Ellard GA, Newton D, Mitchison DA. 1973. Pyrazinamide and other drugs in tuberculous meningitis. Lancet 2:374.
98. Brechbuhler S, Fluehler H, Riess W, Theobald W. 1978. The renal elimination of rifampicin as a function of the oral dose. A convenient way to assess relative bioavailability. Arzneimittelforschung 28:480-483.
99. Acocella G, Bonollo L, Mainardi M, Margaroli P, Tenconi LT. 1977. Serum and urine concentrations of rifampicin administered by intravenous infusion in man. Arzneimittelforschung 27:1221-1226. (Pubitemid 8120239)
100. Ellard GA, Fourie PB. 1999. Rifampicin bioavailability: A review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. Int J Tuberc Lung Dis 3:S301-S308, discussion S317-S321.
101. Schuetz EG, Schinkel AH, Relling MV, Schuetz JD. 1996. P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 93:4001-4005. (Pubitemid 26144235)
102. Schuetz EG, Beck WT, Schuetz JD. 1996. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311-318. (Pubitemid 26066117)
103. Khalil SAH, Elkhordagui LK, Elgholmy ZA. 1984. Effect of antacids on oral absorption of rifampicin. Int J Pharm 20:99-106. (Pubitemid 14091711)
104. Sadeghi S, Karimi E. 2006. Spectrophotometric determination of rifampicin through chelate formation and charge transfer complexation in pharmaceutical preparation and biological fluids. Chem Pharm Bull (Tokyo) 54:1107-1112. (Pubitemid 44166400)
105. Ganescu I, Bratulescu G, Lilea B, Ganescu A, Barbu A. 2002. Chromium anion complexes and drug analysis-Quantitative determination of rifampicin. Acta Chim Slov 49:339-345.
106. Boman G, Lundgren P, Stjernstrom G. 1975. Mechanism of the inhibitory effect of PAS granules on the absorption of rifampicin: Adsorption of rifampicin by an excipient, bentonite. Eur J Clin Pharmacol 8:293-299.
107. Mannisto P. 1977. Absorption of rifampin from various preparations and pharmaceutic forms. Clin Pharmacol Ther 21:370-374. (Pubitemid 8064259)
108. Chouchane N, Barre J, Toumi A, Tillement JP, Benakis A. 1995. Bioequivalence study of two pharmaceutical forms of rifampicin capsules in man. Eur J Drug Metab Pharmacokinet 20:315-320. (Pubitemid 26128621)
109. Pahkla R, Lambert J, Ansko P, Winstanley P, Davies PD, Kiivet RA. 1999. Comparative bioavailability of three different preparations of rifampicin. J Clin Pharm Ther 24:219-225. (Pubitemid 29354039)
110. Panchagnula R, Agrawal S. 2004. Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin. Int J Pharm 271:1-4. (Pubitemid 38210078)
111. Laegemiddel Styrelson Danish Medicines Agency (accessed 03-03-2008). http://www.dkma.dk.
112. National Agency for Medicines, Helsinki, Finland: The National Agency for Medicines responsibilities are to maintain and promote the safety and safe use of medicinal products, medical devices and blood products. (accessed 03-03-2008). www. nam.fi.
113. Thériaque (Centre National Hospitalier d'Information sur le Médicament) (accessed 04-103- 2008). http://www.theriaque.org.
114. College ter Beoordeling van Geneesmiddelen Medicines Evaluation Board of The Netherlands (accessed 04-03-2008). www.cbg-meb.nl.
115. Statens legemiddelverk, Norvegian Medicines Agency (accessed 04-03-2008). www.legemiddelverket. no.
116. Agencia Españ ola de Medicamentos y Productos Sanitarios (accessed 03-03-2008). http://www. agemed.es.
117. Läkemedelsverket. Medical Product Agency Sweden (accessed 04-03-2008). http://www.lakemedelsverket. se.
118. The medicines information web site provided by Datapharm Communications Ltd. (accessed 04- 03-2008). www.medicines.org.uk.
119. DailyMed Current Medication Information, U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894. National Institutes of Health, Health & Human Services (accessed 04-03-2008). www.dailymed.nlm.nih. gov.
120. Gleiter CH, Gundert-Remy U. 1994. Bioinequivalence and drug toxicity. How great is the problem and what can be done? Drug Saf 11:1-6.
121. Gleiter CH, Klotz U, Kuhlmann J, Blume H, Stanislaus F, Harder S, Paulus H, Poethko-Muller C, Holz-Slomczyk M. 1998. When are bioavailability studies required? A German proposal. J Clin Pharmacol 38:904-911. (Pubitemid 28482115)
122. The Inactive Ingredients Database, U.S. Food and Drug Administration Center for Drug Evaluation and Research (accessed 04-03-2008). http://www. fda.gov/cder/iig/iigfaqWEB.htm#purpose.
123. Agrawal S, Panchagnula R. 2004. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations. Int J Pharm 287:97-112. (Pubitemid 39487248)
124. Rao BS, Murthy KV. 2002. Studies on rifampicin release from ethylcellulose coated nonpareil beads. Int J Pharm 231:97-106. (Pubitemid 33086823)
125. McColl KE. 1996. Helicobacter pylori, gastric acid, and duodenal gastric metaplasia. Gut 39:615-616. (Pubitemid 26376050)
126. Yee S. 1997. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - Fact or myth. Pharm Res 14:763-766.
127. Lindenberg M, Kopp S, Dressman JB. 2004. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 58:265-278. (Pubitemid 39037234)
128. Wu CY, Benet LZ. 2005. Predicting drug disposition via application of BCS: Transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23. (Pubitemid 40558141)
129. Agrawal S, Panchagnula R. 2004. In vitro evaluation of fixed dose combination tablets of antituberculosis drugs after real time storage at ambient conditions. Pharmazie 59:782-785.
130. Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R. 2004. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels. Int J Pharm 276:41-49. (Pubitemid 38542986)
131. Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R. 2002. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations. Int J Clin Pharmacol Ther 40:474-481.
132. Agrawal S, Kaur KJ, Singh I, Bhade SR, Kaul CL, Panchagnula R. 2002. Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels. Int J Pharm 233:169-177. (Pubitemid 34230429)
133. Panchagnula R, Sancheti P, Rungta S, Agrawal S, Kaul CL. 2003. Evaluation of bioequivalence of isoniazid and pyrazinamide in three and four drugs fixed dose combinations using WHO simpli- fied protocol. Pharmacol Res 48:383-387. (Pubitemid 36945337)
134. Gurumurthy P, Ramachandran G, Vijayalakshmi S, Kumar AK, Venkatesan P, Chandrasekaran V, Vjayasekaran V, Kumaraswami V, Prabhakar R. 1999. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: Comparison of plasma and urine kinetics. Int J Tuberc Lung Dis 3:119-125. (Pubitemid 29151814)
135. Jindani A, Aber VR, Edwards EA, Mitchison DA. 1980. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 121:939-949. (Pubitemid 10118376)
136. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, Matter L, Schopfer K, Bodmer T. 1993. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341:647-650. (Pubitemid 23083244)
137. Agal S, Baijal R, Pramanik S, Patel N, Gupte P, Kamani P, Amarapurkar D. 2005. Monitoring and management of antituberculosis drug induced hepatotoxicity. J Gastroenterol Hepatol 20: 1745-1752. (Pubitemid 43961083)
138. Holdiness MR. 1989. A review of the Redman syndrome and rifampicin overdosage. Med Toxicol Adverse Drug Exp 4:444-451. (Pubitemid 19264127)
139. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), September 1997, CMC 8; Guidance for Industry SUPAC-MR: Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation. ed. http://www.fda.gov/CDER/ GUIDANCE/1214fnl.pdf.
140. U.S. Department of Health and Human Services Food and Drug Administration Center for Evaluation and Research (CDER).1995. Guidances for industry: Immediate Release Solid Oral Dosage Forms. Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation. http://www.fda.gov/ CDER/GUIDANCE/cmc5.pdf.